A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia
Authors:
Open Access
- 25 February 2016
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 263 (4) , 772-780
Abstract
A systematic pair-wise comparison of all available botulinum toxin serotype A and B treatments for cervical dystonia (CD) was conducted, as direct head-to-head clinical trial comparisons are lacking. Five botulinum toxin products: Dysport® (abobotulinumtoxinA), Botox® (onabotulinumtoxinA), Xeomin® (incobotulinumtoxinA), Prosigne® (Chinese botulinum toxin serotype A) and Myobloc® (rimabotulinumtoxinB) have demonstrated efficacy for managing CD. A pair-wise efficacy and safety comparison was performed for all toxins based on literature-reported clinical outcomes. Multi-armed randomized controlled trials (RCTs) were identified for inclusion using a systematic literature review, and assessed for comparability based on patient population and efficacy outcome measures. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) was selected as the efficacy outcome measurement for assessment. A mixed treatment comparison (MTC) was conducted using a Bayesian hierarchical model allowing indirect comparison of the interventions. Due to the limitation of available clinical data, this study only investigated the main effect of toxin treatments without explicitly considering potential confounding factors such as gender and formulation differences. There was reasonable agreement between the number of unconstrained data points, residual deviance and pair-wise results. This research suggests that all botulinum toxin serotype A and serotype B treatments were effective compared to placebo in treating CD, with the exception of Prosigne. Based on this MTC analysis, there is no significant efficacy difference between Dysport, Botox, Xeomin and Myobloc at week four post injection. Of the adverse events measured, neither dysphagia nor injection site pain was significantly greater in the treatment or placebo groups.Keywords
This publication has 35 references indexed in Scilit:
- Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystoniaJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Abo‐, Inco‐, Ona‐, and Rima‐Botulinum Toxins in Clinical Therapy: A PrimerPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapyJournal of Neural Transmission, 2012
- Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystoniaJournal of the Neurological Sciences, 2011
- Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: Randomized, double‐blind, noninferiority trialMovement Disorders, 2007
- Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN??) in Focal DystoniaDrugs, 2007
- Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in Medicine, 2004
- Meta-Analysis of Migraine Headache Treatments: Combining Information from Heterogeneous DesignsJournal of the American Statistical Association, 1999
- Meta-analysis of Multitreatment StudiesMedical Decision Making, 1998
- Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, MinnesotaMovement Disorders, 1995